DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Scleroderma (Systemic Sclerosis) | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2019
Systemic sclerosis (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that manifests as Raynaud’s disease and, often, painful…
Graft-Versus-Host Disease | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2019
GVHD is a potentially life-threatening complication of allogenic HCST. GVHD is a systemic inflammatory reaction triggered by donor T cells’ recognition of host cell antigens in nontarget tissue…
Malignant Melanoma | Unmet Need | BRAF-mutation-positive Unresectable or Metastatic | US/EU | 2019
Treatment of BRAF-mutation-positive unresectable or metastatic malignant melanoma has been transformed by the development of several combination regimens that include BRAF and MEK inhibitors, as…
Immune Checkpoint Inhibitors in Bladder Cancer, NSCLC, and Malignant Melanoma | Access & Reimbursement | US | 2019
Immune checkpoint inhibitors have revolutionized the treatment of multiple oncology indications, including non-small-cell lung cancer (NSCLC), malignant melanoma, and bladder cancer. As premium-…
Special Focus on Retinal Therapies: Payer Management of the Medical Benefit | Access & Reimbursement | US | 2019
As part of ongoing efforts to address the rising cost of pharmaceuticals, the U.S. Centers for Medicare & Medicaid Services significantly shifted policy to allow Medicare Advantage plans to impose…
Amyotrophic Lateral Sclerosis | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2019
Amyotrophic lateral sclerosis (ALS) is a degenerative motor neuron disorder that leads to progressive muscle wasting and weakness. The typical survival time is three to five years from onset. The…
